Hemangiopericytoma and antiangiogenic therapy: clinical benefit of antiangiogenic therapy (sorafenib and sunitinib) in relapsed malignant haemangioperyctoma /solitary fibrous tumour

Invest New Drugs. 2010 Apr;28(2):199-202. doi: 10.1007/s10637-009-9249-1. Epub 2009 Apr 8.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Angiogenesis Inhibitors / therapeutic use*
  • Benzenesulfonates / therapeutic use*
  • Fatal Outcome
  • Female
  • Hemangiopericytoma / blood supply*
  • Hemangiopericytoma / diagnostic imaging
  • Hemangiopericytoma / drug therapy
  • Humans
  • Indoles / therapeutic use*
  • Middle Aged
  • Neovascularization, Pathologic / diagnostic imaging
  • Neovascularization, Pathologic / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Pyridines / therapeutic use*
  • Pyrroles / therapeutic use*
  • Recurrence
  • Solitary Fibrous Tumors / blood supply*
  • Solitary Fibrous Tumors / diagnostic imaging
  • Solitary Fibrous Tumors / drug therapy*
  • Sorafenib
  • Sunitinib
  • Tomography, X-Ray Computed
  • Ultrasonography

Substances

  • Angiogenesis Inhibitors
  • Benzenesulfonates
  • Indoles
  • Phenylurea Compounds
  • Pyridines
  • Pyrroles
  • Niacinamide
  • Sorafenib
  • Sunitinib